马斯克旗下脑机公司：已为全球12人植入芯片

Core Viewpoint - Neuralink has made significant progress in its brain-machine interface technology, with 12 patients having undergone trials of its N1 chip, totaling over 15,000 hours of usage [1][4]. Progress - Neuralink was founded in 2016 with the aim of developing high-bandwidth, minimally invasive brain-machine interface devices for direct communication between the human brain and computers [5]. - The company received FDA approval to begin human trials in 2024 after addressing safety concerns raised by the agency, which had previously rejected its application in 2022 [5]. - In June, Neuralink completed a $650 million Series E funding round, raising its valuation to $9 billion, moving towards a target of $10 billion [6]. - In July, Neuralink announced plans to conduct clinical trials in the UK to test how its chip can assist severely paralyzed patients in controlling digital and physical tools through thought, in collaboration with University College London Hospital and Newcastle Hospital [7]. - Elon Musk indicated that Neuralink may attempt to restore partial vision for visually impaired patients as early as 2026, with the first successful implantation of its "Telepathy" device occurring outside the US [7].